Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants.

NCT05039515 is registered in ClinicalTrials.gov with Clementia Pharmaceuticals Inc. as lead sponsor.

NCT NCT05039515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants.
Lead sponsor
Clementia Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 1, 2021
Completion date
March 27, 2026
Enrollment
113 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva